Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: An analysis of individual patient-level data Academic Article uri icon

Overview

MeSH Major

  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Immunoglobulin Fab Fragments
  • Polyethylene Glycols

abstract

  • Although patient heterogeneity in clinical settings is acknowledged, the present results indicate that increasing the dose of CZP from 200 mg to 400 mg offers little additional benefit in RA, even for selected patients.

publication date

  • August 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/art.30387

PubMed ID

  • 21484766

Additional Document Info

start page

  • 2203

end page

  • 8

volume

  • 63

number

  • 8